Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

General Chapter ⟨1225⟩ Validation of Compendial Procedures

United States Pharmacopeial Convention. United States Pharmacopeia — National Formulary (USP–NF) 2024

Document identifier
CEI-BR-110
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
United States Pharmacopeial Convention
Title
General Chapter ⟨1225⟩ Validation of Compendial Procedures
Source
United States Pharmacopeia — National Formulary (USP–NF)
Year
2024
Volume, issue, pages
USP 2024 Issue 1
Digital object identifier
not held by the Institute
PubMed identifier
not held by the Institute
Record type
Guideline
Institute identifier
CEI-BR-110

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Standard CEI-MS-01: Determination of chromatographic purity of synthetic peptides by…Methodological standard
Standard CEI-MS-02: Confirmation of peptide identity by liquid chromatography–tandem mass…Methodological standard
Standard CEI-MS-03: Determination of peptide content and its distinction from…Methodological standard
Standard CEI-MS-07: Sub-visible particulate matter in reconstituted peptide solutionsMethodological standard
Standard CEI-MS-08: Related-substances profiling and the detection of isobaric impuritiesMethodological standard
Standard CEI-MS-10: Identification and quantification of counter-ions in synthetic…Methodological standard
Standard CEI-MS-12: Residual solvent determination by static headspace gas chromatographyMethodological standard
Standard CEI-MS-13: Development and validation of a stability-indicating method for…Methodological standard
Standard CEI-MS-14: Certificate-of-analysis minimum data standard for synthetic peptide…Methodological standard
Standard CEI-MS-15: Protocol for independent third-party verification of a supplied…Methodological standard
Standard CEI-MS-19: Purity determination for peptides not retained by conventional…Methodological standard
Standard CEI-MS-20: Photostability assessment of light-sensitive peptidesMethodological standard
Synthesis: Completeness of certificates of analysis in the research-supply…Evidence synthesis
Synthesis: Counter-ion content and its effect on delivered peptide massEvidence synthesis
Synthesis: Dependence of reported purity on the analytical methodEvidence synthesis
15 citing documents.

§1.3Subject tags

validation method usp

Compound Evidence Institute · CEI-BR-110 · https://compoundevidence.com/bibliography/usp1225/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.